Business Wire24d
PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia
SURPASS-ET Clinical Results Clinical Trial Overview SURPASS-ET (NCT04285086) is a global Phase 3, randomized, open-label, active-controlled clinical trial evaluating the efficacy, safety and ...
Hosted on MSN22d
J&J reports positive topline outcomes from Phase III NSCLC combo therapy trial
The median OS improvement is anticipated to surpass one year ... "J&J reports positive topline outcomes from Phase III NSCLC combo therapy trial" was originally created and published by Clinical ...
AZOM3y
Streaming Answers: SurPASS™ 3
Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...
WRAL1mon
An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late ...